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Abstract
Introduction Little is known about systemic B-cell activation in
early rheumatoid arthritis (RA). We therefore evaluated the
serum levels of markers of B-cell activation in patients included
in the ESPOIR early arthritis cohort.
Methods In the ESPOIR early arthritis cohort (at least 2 swollen
joints for more than 6 weeks but less than 6 months), 710
patients were assessed at 1 year and either met the 1987
American College of Rheumatology criteria for RA (n = 578) or
had undifferentiated arthritis (n = 132). Baseline serum samples
of patients naïve to corticosteroid and disease-modifying
antirheumatic drug treatment were assessed for beta2-
microglobulin, IgG, IgA, IgM, immunoglobulin free light chains of
immunoglobulins, and B-cell activating factor of the tumor
necrosis factor family (BAFF). The BAFF gene 871T>C
polymorphism was genotyped in all patients.
Results All markers of B-cell activation except BAFF and IgM
were significantly higher in patients with early RA than those
with undifferentiated arthritis. Anti-cyclic citrullinated peptide
(anti-CCP) and beta2-microglobulin were associated with a
diagnosis of early RA in the multivariate analysis. Markers of B-
cell activation, except BAFF, were associated with disease
activity, rheumatoid factor and anti-CCP secretion. The BAFF
gene polymorphism was not associated with early RA.
Conclusions Markers of B-cell activation are elevated in
patients with early RA, compared with undifferentiated arthritis,
independently of any systemic increase in BAFF secretion, and
correlate with disease activity. This study sheds new light on the
early pathogenic role of B-lymphocytes in RA and suggests that
targeting them might be a useful therapeutic strategy in early
RA.
Introduction
For decades – ever since the discovery of rheumatoid factor
(RF) – B cells have been known to play a pathogenic role in
established rheumatoid arthritis (RA) [1-4]. More recently, the
secretion of RF and antibodies against cyclic citrullinated pep-
tide (anti-CCP) was demonstrated to precede RA clinical
onset by many years [5,6], which suggests that activation of
autoreactive B cells might be an early pathogenic event. How-
ever, very little is known about the activation of alloreactive B
cells in patients with early RA. Markers of B-cell activation,
such as beta2-microglobulin, immunoglobulin levels, free light
chains (FLCs) of immunoglobulins, and BAFF (B-cell activat-
ACR: American College of Rheumatology; anti-CCP: anti-cyclic citrullinated peptide; APRIL: a proliferation-inducing ligand; BAFF: B-cell activating 
factor of the tumor necrosis factor family; CRP: C-reactive protein; DAS28: disease activity score using 28 joint counts; DMARD: disease-modifying 
antirheumatic drug; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; FLC: free light chain; HAQ: Health Assess-
ment Questionnaire; IL: interleukin; OR: odds ratio; RA: rheumatoid arthritis; RF: rheumatoid factor; SLE: systemic lupus erythematosus; TNF: tumor 
necrosis factor; UA: undifferentiated arthritis; VAS: visual analog scale.
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ing factor of the tumor necrosis factor [TNF] family) – which
are all elevated in established RA [7-10] – could be useful in
determining the extent of B-cell activation in early RA. One of
the objectives of the French multicenter prospective cohort,
ESPOIR [11], is to determine the specific biological features
of early RA by comparing serum samples from patients with
either early RA or other early arthritis who are naïve to disease-
modifying antirheumatic drugs (DMARDs) and steroids. In this
study, we assessed baseline levels of several markers of non-
specific B-cell activation, such as beta2-microglobulin, immu-
noglobulin FLCs, IgG, IgA, and IgM as well as serum BAFF.
Since the BAFF 871T>C polymorphism is reported to be cor-
related with serum BAFF level in various diseases [12-14],
patients were also genotyped for this polymorphism. Our find-
ings show that baseline serum markers of B-cell activation are
higher in patients with early RA than in patients with undiffer-
entiated arthritis (UA). In addition, their increase is correlated
with disease activity but is independent of serum BAFF levels
and the BAFF gene polymorphism.
Materials and methods
Patients
The French multicenter prospective cohort of patients with
early arthritis (ESPOIR) has included 813 patients with early
arthritis between December 2002 and March 2005 and plans
to follow them for 10 years. Patients were eligible for inclusion
in the cohort if they had a definitive or probable clinical diag-
nosis of RA or a diagnosis of UA with a potential for progress-
ing to RA. Thus, these patients had at least two swollen joints,
present for more than 6 weeks but less than 6 months, and
were naïve for DMARDs and corticosteroids at inclusion. Their
baseline clinical, immunological, and radiological features
were recently published [11,15]. Eighty-three patients missed
the 1-year visit and were not included in the present study.
Twenty patients fulfilling American College of Rheumatology
(ACR) or international consensus group criteria for other
arthritides were excluded. Diagnosis of RA was defined after
1 year of follow-up, according to cumulative 1987 ACR criteria
for RA (independently from the positivity for anti-CCP).
Patients without any definite diagnosis until the 1-year follow-
up visit were diagnosed with UA. The present study thus ana-
lyzes the 710 patients who completed the first three visits (at
baseline, 6 months, and 1 year) and were diagnosed as having
RA or UA after 1 year of follow-up. Serum samples from 80
healthy blood donors were assessed for BAFF levels, and
DNA samples from 90 healthy blood donors were assessed
for the BAFF gene polymorphism. The Montpellier Ethics
Committee approved the study in July 2002, and all patients
and controls provided informed consent.
Serum assessments
Serum samples were collected at enrollment and immediately
stored at -80°C. One biological resource center was in charge
of centralizing and managing biological data collection.
Assessments of serum beta2-microglobulin, IgG, IgA, IgM,
immunoglobulin FLCs (nephelometry), and BAFF (enzyme-
linked immunosorbent assay, or ELISA; R&D Systems, Lille,
France) were centralized. Serum samples of 40 patients were
simultaneously thawed daily, and all of their markers of B-cell
activation were assessed that day. Serum measurements of
IgM and IgA RF (ELISA; Menarini France, Rungis Cedex,
France, positive >9 IU/mL) and anti-CCP (anti-CCP2; Dia-
Sorin, Saluggia [Vercelli], Italy, positive >50 U/mL) levels were
performed in a central location and determined as previously
reported [11].
DNA genotyping
After genomic DNA was isolated from peripheral blood mono-
nuclear cells, the BAFF promoter gene polymorphism
871T>C was genotyped with competitive allele-specific
polymerase chain reaction by using FRET (fluoroscence reso-
nance energy transfer) technology. This genotyping was suc-
cessful for 686 patients and 90 healthy blood donors.
Radiological data
At enrollment, radiographs of the hands and wrists (anteropos-
terior view) and of the feet (anteroposterior and oblique views)
were taken. Their interpretation was standardized as
described previously [11,15].
Statistical analysis
Continuous data are presented as medians with interquartile
ranges. In spite of the high number of patients and because of
the uneven frequency of early RA and UA data, we used non-
parametric tests for statistical analysis of continuous variables.
The Mann-Whitney U test was used to compare continuous
data between patients with RA and patients with UA or, within
the RA group, between patients with or without RF, anti-CCP,
or radiological erosions. The chi-square test was used to com-
pare BAFF allele and genotype frequencies between patients
with RA, patients with UA, and controls. The chi-square test
was also used to compare the proportion of anti-CCP
between RA patients and UA patients and, within the RA
group, to compare the proportion of RF and anti-CCP
between patients with and without early erosions. Correlations
between disease activity score using 28 joint counts (DAS28)
or Health Assessment Questionnaire (HAQ) and markers of B-
cell activation were studied with the Spearman rank test. Bio-
logical markers associated on univariate analysis with type of
arthritis (RA or UA: erythrocyte sedimentation rate [ESR], C-
reactive protein [CRP], anti-CCP, IgG, IgA, beta2-microglobu-
lin, and kappa and lambda FLCs of immunoglobulins) or, in RA,
with the presence of initial erosions (IgM-RF, IgA-RF, anti-
CCP, ESR, IgA, and kappa FLCs of immunoglobulins) were
included in multivariate logistic regression models. Statistical
analyses were performed with Stata SE 9.2 (StataCorp LP,
College Station, TX, USA).
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Results
Characteristics of the study population
The median age of the 710 patients (76.5% of whom were
female) was 49 (40 to 64) years. At enrollment, 48.3% of the
patients were IgM-RF-positive and 40.0% were anti-CCP-pos-
itive. Median DAS28 was 5.1 (4.3 to 5.9), and median HAQ
was 0.9 (0.4 to 1.4). Radiographic erosions on hands or feet
were seen at inclusion in 22.5% of the patients. Five hundred
seventy-eight patients (79.2%) had met the 1987 ACR criteria
for RA at any time since their inclusion and were classified as
having early RA, and 132 patients still had UA at the 1-year fol-
low-up visit. Baseline characteristics of the 710 patients are
summarized in Table 1.
Elevated markers of B-cell activation in patients with 
early rheumatoid arthritis
Comparison of markers of B-cell activation, except RF, which
belongs to ACR criteria used to define RA, was performed
between patients with early RA and patients with UA. Patients
with early RA had significantly elevated serum levels of beta2-
microglobulin, IgG, IgA, and immunoglobulin kappa and
lambda FLCs. Anti-CCP, ESR, and CRP were also associated
on univariate analysis with the diagnosis of early RA (Table 1).
In the multivariate analysis, which included all markers associ-
ated with RA on univariate analysis, diagnosis of RA after 1
year of follow-up was associated with levels of anti-CCP (odds
ratio [OR] 5.8 [3.4 to 10.0], P = 0.001) and beta2-microglob-
ulin (OR 1.5 [1.0 to 2.0], P = 0.03) and tended, though not
significantly, to be associated with IgA levels (OR 1.2 [0.9 to
1.5], P = 0.06).
Serum BAFF levels in patients with early rheumatoid 
arthritis and with undifferentiated arthritis
BAFF was a possible explanation for the higher levels of mark-
ers of B-cell activation in early RA. The median BAFF levels
were 0.7 (0.5 to 1.0) ng/mL in the 710 patients with arthritis
and 0.5 (0.4 to 0.6) ng/mL in the 80 healthy blood donors (P
<0.0001). However, BAFF levels were similar in patients with
early RA (0.7 [0.5 to 1.0]) and those with UA (0.7 [0.5 to 0.9],
P = 0.5) (Table 1).
Association of the BAFF 871T>C gene promoter 
polymorphism with early rheumatoid arthritis and 
undifferentiated arthritis
We analyzed the distribution of the BAFF 871T>C polymor-
phism among patients with early RA and patients with UA. The
two groups did not differ significantly for any allelic or geno-
typic frequencies (Table 2). Likewise, the allelic and genotypic
Table 1
Baseline characteristics of 710 patients with early rheumatoid arthritis or undifferentiated arthritis
Patients with early RA or UA Early RA UA Univariate analysis:
P value
Multivariate analysis:
OR (95% CI), P value
(1) (2) (1) versus (2) (1) versus (2)
n = 710 n = 578 n = 132
Percentage of females 76.5% 77% 74% 0.8
Age, years 49.0 (40.0–64.0) 50.1 (42.3–65.2) 47.4 (39.5–62.4) 0.6
ESR, mm at 1st hour 22.0 (11.2–38) 23.0 (12.0–40.1) 17.0 (10.0–32.0) 0.01 0.9 (0.9–1.0), 0.6
CRP, mg/L 9.0 (0–24.0) 9.5 (3.0–25.0) 6.0 (0–16.0) 0.002 1.0(0.9–1.1), 0.3
Positivity for anti-CCP 40.3% 47.4% 13.2% <0.0001 5.8 (3.4–10.0), 0.001
BAFF, ng/mL 0.7 (0.5–1.0) 0.7 (0.5–1.0) 0.7 (0.5–0.9) 0.5
Beta2–microglobulin, mg/L 1.9 (1.7–2.3) 2.0 (1.7–2.4) 1.8 (1.6–2.1) 0.0002 1.5 (1.0–2.0), 0.03
Total IgG, g/L 13.5 (11.5–16.1) 13.5 (11.7–16.1) 12.9 (10.9–16.0) 0.03 0.9 (0.9–1.0), 0.4
Total IgA, g/L 2.6 (1.9–3.5) 2.8 (1.9–3.5) 2.2 (1.7–3.1) <0.0001 1.2 (0.9–1.5), 0.06
Total IgM, g/L 1.5 (1.1–2.0) 1.5 (1.1–2.0) 1.4 (1.1–1.9) 0.5
Kappa free light chain, mg/L 13.8 (10.5–17.9) 14.3 (10.9–18.7) 11.7 (9.6–14.9) <0.0001 1.0 (0.9–1.0), 0.6
Lambda free light chain, mg/
L
16.4 (12.8–21.6) 17.5 (13.2–22.5) 14.5 (11.6–18.8) <0.0001 0.9 (0.9–1.0), 0.9
Ratio of kappa to lambda 0.8 (0.3–0.99) 0.8 (0.7–1.0) 0.8 (0.7–0.9) 0.9
Results are expressed as median values (25th–75th values) or as percentages. Comparison of proportions of presence of anti-cyclic citrullinated 
peptide (anti-CCP) used chi-square test, and comparison of the other variables used Mann-Whitney U test. Baseline markers associated on 
univariate analysis with rheumatoid arthritis (RA) diagnosis were analyzed in multivariate analysis. BAFF, B-cell activating factor of the tumor 
necrosis factor family; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; OR, odds ratio; UA, undifferentiated 
arthritis.
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frequencies in early RA patients did not differ significantly from
those in healthy controls. This polymorphism was not associ-
ated with any baseline characteristic of early RA: DAS28 (P =
0.46), erosive arthritis (P = 0.2), RF (P = 0.9), and anti-CCP
(P = 0.2). BAFF levels were similar in the early RA patients
regardless of genotype for the BAFF 871T>C polymorphism
(P = 0.2). No BAFF gene polymorphism was associated with
serum BAFF level in the overall patient cohort either (P = 0.1).
Association of markers of B-cell activation with initial 
disease activity, Health Assessment Questionnaire, 
autoantibody secretion, and early erosion in patients 
with early rheumatoid arthritis
We subsequently investigated whether an elevated level of
markers of B-cell activation was associated with a specific
clinical, immunological, or radiological pattern in patients with
early RA. The initial DAS28 was slightly but significantly corre-
lated with serum levels of beta2-microglobulin (r = 0.2, P
<0.0001), IgG (r = 0.3, P <0.0001), IgA (r = 0.2, P <0.0001),
IgM (r = 0.1, P = 0.002), and kappa and lambda FLCs (r = 0.3,
P <0.0001 for both) but not BAFF, IgM-RF, IgA-RF, or anti-
CCP. Initial HAQ was slightly but significantly correlated with
all initial markers of B-cell activation except IgA-RF (data not
shown). Among patients with early RA, levels of IgG, IgA, IgM,
and kappa and lambda FLCs were significantly higher in early
RA patients positive for IgM-RF or anti-CCP antibodies than in
those negative for them (Table 3). IgA levels were higher in
patients with IgA-RF than in those without IgA-RF (3.2 [2.5 to
3.9] versus 2.3 [1.7 to 2.9], P <0.0001). BAFF levels were
similar regardless of the presence of autoantibodies (Table 3).
Serum levels of BAFF, beta2-microglobulin, IgG, IgM, and
lambda FLCs were not associated with the presence of radio-
Table 2
Allelic and genotypic distribution of BAFF -871T/C among patients with early rheumatoid arthritis, undifferentiated arthritis, and 
controls
BAFF -871T/Caia Early RA UA Controls P value Odds ratio (95% CI) P value Odds ratio (95% CI)
Allele frequencies n = 1,112 n = 260 n = 180 Early RA versus UA Early RA versus controls
-871C (%) 603 (54) 146 (56) 90 (50) NS 1.00 (0.77–1.30) NS 1.18 (0.86–1.62)
-871T (%) 509 (46) 114 (44) 90 (50)
Genotype frequencies n = 556 n = 130 n = 90
CC (%) 171 (31) 43 (33) 21 (23) NS 1.02 (0.68–1.53)
CC versus CT and TT
NS 1.46 (0.87–2.46) CC versus CT and TT
CT (%) 261 (47) 60 (46) 48 (54)
TT (%) 124 (22) 27 (21) 21 (23) NS 1.02 (0.66–1.60)
TT versus CT and CC
NS 0.94 (0.56–1.60) TT versus CT and CC
Comparisons used chi-square test. BAFF, B-cell activating factor of the tumor necrosis factor family; CI, confidence interval; NS, not significant; 
RA, rheumatoid arthritis; UA, undifferentiated arthritis.
Table 3
Association between baseline B-cell activation biomarkers and immunological features of the 578 patients with early rheumatoid 
arthritis
IgM RF + IgM RF - P value Anti-CCP + Anti-CCP - P value
n = 321 n = 257 n = 274 n = 304
BAFF 0.7 (0.5–0.9) 0.7 (0.5–1.0) 0.18 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.18
Beta2–microglobulin 2.1 (1.8–2.4) 1.9 (1.6–2.3) 0.01 2.0 (1.7–2.4) 1.9 (1.6–2.4) 0.30
Total IgG 14.0 (12.0–16.9) 13.0 (11.1–15.1) <10-4 14.4 (12.4–17.1) 12.9 (11.1–15.9) <10-4
Total IgA 2.9 (2.1–3.7) 2.5 (1.9–3.3) <10-4 3.1 (2.3–3.8) 2.4 (1.8–3.2) <10-4
Total IgM 1.6 (1.2–2.2) 1.3 (1.1–1.8) <10-4 1.6 (1.2–2.3) 1.4 (1.0–1.9) <10-4
Kappa free light chain 15.8 (12.2–20.6) 12.7 (9.5–16.8) <10-4 16.3 (12.7–20.6) 12.7 (9.7–17.1) <10-4
Lambda free light chain 18.6 (14.4–25.0) 15.0 (11.8–19.6.) <10-4 19.3(14.9–24.9) 15.1 (11.9–19.9) <10-4
Results are expressed as median values (25th–75th values). B-cell activating factor of the tumor necrosis factor family (BAFF) values are 
expressed in nanograms per milliliter, total immunoglobulin values in grams per liter, and free light chain of immunoglobulins in milligrams per liter. 
Comparisons used Mann-Whitney U test. Anti-CCP, anti-cyclic citrullinated peptide; RF, rheumatoid factor.
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logical erosions at enrollment. Conversely, levels of total IgA
and kappa FLCs were significantly higher in patients with ero-
sion (3.0 [2.1 to 3.7] g/L and 15.3 [11.9 to 20.7] mg/L,
respectively) than without erosion (2.6 [1.9 to 3.4] g/L and
13.9 [10.4 to 17.9] mg/L, P = 0.003 and P = 0.007). On uni-
variate analysis, other parameters associated with radiological
erosions at enrollment included IgM-RF, IgA-RF, anti-CCP,
and ESR (Table 4). In the multivariate analysis, only anti-CCP
(OR 2.3 [1.2 to 4.3], P = 0.008) and IgA-RF positivity (OR 1.7
[1.1 to 2.7], P = 0.01) were associated with early erosions
(Table 4).
Discussion
These findings from ESPOIR, the prospective French multi-
center cohort of early arthritis patients, demonstrate that
serum markers of B-cell activation are elevated in patients with
early RA compared with undifferentiated early arthritis. They
also show that markers of B-cell activation are correlated with
disease activity. Lastly, they indicate that serum BAFF might
not drive the specific B-cell activation we observed in early RA.
ESPOIR offered us the opportunity to investigate markers of
B-cell activation in patients with early arthritis who had not yet
been exposed to corticosteroids or DMARDs at enrollment.
The disease-related increase of markers of B-cell activation
might otherwise have been masked by these treatments,
which can modulate these marker levels [16,17]. Another obvi-
ous advantage of performing such a study with this cohort was
the centralization of biological, immunological, and radiological
examinations and the prospective follow-up, which allows us
to determine whether markers of B-cell activation can serve as
predictive factors of long-term clinical activity.
The main limitations of this study were the short duration of fol-
low-up (1 year) so far, since ACR criteria for RA might be ful-
filled later, and the absence of validated criteria for early RA.
Although the 1987 ACR criteria lack specificity for early RA
diagnosis [18], they remain widely used in patients with early
arthritis in the absence of any other international criteria for
early RA. The percentage of patients who fulfilled these 1987
ACR criteria of RA is higher in the ESPOIR cohort (72% at
inclusion and 79% at 1 year) than in other early arthritis
cohorts [19,20]. This may be related to the inclusion criteria of
ESPOIR, which were more stringent (at least two swollen
joints and 6 weeks of duration) than those of some other early
arthritis cohorts. It has been suggested that the specificity of
ACR criteria in early RA may improve when the physician's
level of confidence in the RA diagnosis is high [18]. At the
ESPOIR 1-year follow-up visit, the rheumatologists completed
a visual analog scale (VAS) assessing their confidence in the
RA diagnosis for each patient. We were therefore able to con-
duct a separate analysis of the 367 of the 578 patients fulfill-
ing 1987 ACR criteria for RA for whom this VAS was equal to
Table 4
Baseline clinical and biological features in patients with early rheumatoid arthritis according to the presence of radiological 
erosions at enrollment
Early erosions Absence of early erosion Univariate analysis:
P value
Multivariate analysis:
OR (95% CI), P value
n = 138 n = 377
Initial DAS28 5.4 (4.6–6.4) 5.2 (4.3–6.5) 0.1
ESR, mm at 1st hour 29.5 (13.0–54.0) 20.5 (11.0–36.0) 0.002 1.1 (0.9–1.3), 0.4
CRP, mg/L 11.0 (4.0–33.1) 9.0 (0–22.0) 0.1
IgM-RF-positive 63.7% 52.5% 0.03 0.7 (0.4–1.3), 0.2
IgA-RF-positive 64.5% 45.9% 0.0003 1.7 (1.1–2.7), 0.01
Anti-CCP-positive 61.6% 41.6% <0.0001 2.3 (1.2–4.3), 0.008
BAFF, ng/mL 0.7 (0.5–0.9) 0.8 (0.5–1.0) 0.5
Beta2–microglobulin, mg/L 2.1 (1.7–2.4) 1.9 (1.7–2.4) 0.08
Total IgG, g/L 13.7 (12.0–15.6) 13.3 (11.5–15.9) 0.2
Total IgA, g/L 3.0 (2.1–3.7) 2.6 (1.9–3.4) 0.003 1.1 (0.9–1.2), 0.4
Total IgM, g/L 1.4 (1.1–2.1) 1.5 (1.1–2.1) 0.9
Kappa free light chain, mg/L 15.3 (11.9–20.7) 13.9 (10.4–17.9) 0.007 1.0 (0.9–1.1), 0.2
Lambda free light chain, mg/L 18.3 (13.5–23.4) 16.9 (12.8–21.9) 0.1
Results are expressed as median values (25th–75th values) or as percentages. Comparison of proportions of presence of IgM-RF, IgA-RF, and 
anti-cyclic citrullinated peptide (anti-CCP) used chi-square test, and comparison of the other variables used Mann-Whitney U test. Baseline 
markers associated on univariate analysis with early erosions (radiological erosions at enrollment) were analyzed in multivariate analysis. BAFF, B-
cell activating factor of the tumor necrosis factor family; CI, confidence interval; CRP, C-reactive protein; DAS28, disease activity score using 28 
joint counts; ESR, erythrocyte sedimentation rate; OR, odds ratio; RF, rheumatoid factor.
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or greater than 75 mm on a scale of 100 mm. Even when these
more stringent criteria for RA were used, levels of IgG, IgA,
and kappa FLCs remained higher in early RA than in undiffer-
entiated early arthritis (data not shown). Lastly, since few
serum markers of other immune cells are available in routine,
only markers of B-cell activation were assessed in the present
study, which did not address the pathogenic role of other
immune cells.
The ESPOIR cohort confirms the pathogenic activation of
autoreactive B cells in early RA, reflected by the association
between anti-CCP and IgA-RF with early radiological erosions,
also observed in previous early RA cohorts [21,22]. The origi-
nality of the present study is to also assess markers of activa-
tion of alloreactive B cells in early arthritis, such as total levels
of immunoglobulins, FLCs of immunoglobulins, and beta2-
microglobulin.
The first important finding is that serum level markers of allore-
active B-lymphocyte activation are higher in early RA than in
UA. Some features of B-cell activation were nonetheless
observed in patients with UA, including BAFF levels that were
higher than in healthy donors, elevated IgG in 55% of the
patients, and elevated levels of immunoglobulin FLCs in 22%
(compared with 0% in healthy donors, according to previous
studies [9,23]). During follow-up, it will be interesting to study
whether patients with UA and high levels of markers of B-cell
activation may more frequently develop RA or another autoim-
mune disease, such as systemic lupus erythematosus (SLE) or
primary Sjögren syndrome, both of which feature elevated lev-
els of markers of B-cell activation [9]. The markers we
assessed reflect different stages of B-lymphocyte activation.
All of them except IgM and BAFF were elevated in early RA.
Beta2-microglobulin, present at the surface of all nucleated
cells in association with major histocompatibility complex
(MHC) class I molecules, is secreted mainly by B cells and
plasma cells, while plasmablasts and plasma cells secrete
immunoglobulin FLCs. Increased levels of the latter thus sug-
gest that plasmablasts might also be activated in early RA. The
normality of the kappa-to-lambda ratio in nearly all study
patients confirmed that B-cell activation is polyclonal in RA. As
opposed to IgM, IgG and IgA are secreted by mature plasma
cells, which are a terminal stage of B-cell differentiation, after
isotype class switching. A case-control study observed that,
more than 10 years before RA development, future patients
had elevated levels of IgG and IgA, but not of IgM, as in our
patients with early RA [8].
Our second important finding was the absence of an associa-
tion between the BAFF gene polymorphism and either RA or
any of the baseline clinical, immunological, or radiological
characteristics of RA. The lack of an association with RA is
consistent with a previous Japanese genetic study [24]. We
found no association between the BAFF polymorphism and
serum BAFF levels, contrary to findings of our group and oth-
ers in primary Sjögren syndrome and hematological disorders
[12-14], in which the BAFF 871T>C allele was associated
with higher serum levels of the cytokine. This discrepancy may
be due to much higher serum BAFF levels in the diseases in
which this association has been observed. The polymorphism
may thus predispose patients to higher BAFF levels in dis-
eases in which environmental stimulations trigger BAFF secre-
tion.
Serum BAFF level was higher than in healthy blood donors, as
previously reported for patients with established disease
[25,26]. However, BAFF levels did not differ significantly
between patients with early RA and those with undifferentiated
early arthritis. Serum BAFF level was not associated with total
Ig, RF, or anti-CCP levels, disease activity, or initial radiological
erosions. These results are consistent with previous reports
showing no difference in serum BAFF levels for patients with
RA and other arthritides, including SLE, spondylarthropathy,
crystal-induced arthritis, and osteoarthritis [26,27]. One study
found an association between serum BAFF and early RA but
in a much smaller population (n = 48) and with a different tech-
nique for BAFF assessment [28].
Thus, the specific increase of markers of B-cell activation in
early RA might not be related to the increase of BAFF secre-
tion. Membrane-bound BAFF or post-translational changes of
BAFF (glycosylation, trimerization with a proliferation-inducing
ligand [APRIL] or delta BAFF) might affect serum B-cell acti-
vation independently of the quantity of BAFF secreted and
detected in the serum. The role of local BAFF production in
arthritic joints cannot be ruled out either since BAFF levels are
reported to be higher in synovial fluid than in serum [27]. As in
serum, however, these levels in synovial fluid do not differ for
patients with RA and with other inflammatory arthritides [27].
Our results thus suggest that serum BAFF does not drive B-
cell activation in early RA, at least not directly or solely. The
triggering forces of B-cell activation in early RA may depend
on T lymphocytes. A specific pattern of T-lymphocyte activa-
tion was recently reported in RA, with Th2 (interleukin [IL]-4,
IL-13) and IL-17 expression increasing temporarily in the syn-
ovial fluid of patients with very early RA [29]. Th2 profiles favor
B-cell activation and antibody secretion. Among the factors
unrelated to T cells, the role of innate immune cytokines, such
as IL-6, should also be considered.
Interestingly, our results showed elevated serum IgA levels in
early RA. This might be related to synovial, T cell-independent
activation of B lymphocytes, which might be locally triggered
by resident cells of autoimmunity, like synoviocytes, as
described in mucosa [30]. In regard to the cytokine triggers of
IgA increase, transforming growth factor-beta, which
enhances IgA class switching [31], might be involved. T cell-
independent class IgA class switching might also be favored
by APRIL, a cytokine of the TNF family that shares two of the
Available online http://arthritis-research.com/content/11/4/R114
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three receptors of BAFF: B-cell maturation antigen (BCMA)
and TACI (transmembrane activator and CAML [calcium mod-
ulator and cyclophilin ligand] interactor) [10]. APRIL levels are
elevated in synovial fluid from patients with established RA
[27], and synovial expression of APRIL (but not of BAFF) is
reported to be highest in patients with germinal center-like
structures in the synovium, a form of lymphoid organization
known to enhance B-cell activation [32]. Investigation of the
role of APRIL in the B-cell activation of patients with early RA
therefore appears useful.
Lastly, one of the important results of the study was the asso-
ciation observed between the increase in some markers of B-
cell activation and disease activity (assessed by DAS28) and
between the increase in some markers of B-cell activation
(total IgA and kappa FLCs) and disease severity (early radio-
logical erosion at inclusion). The relevance of markers of B-cell
activation as prognostic markers will be further investigated
throughout the cohort study, planned to last for 10 years to
ensure assessment of patients' long-term clinical and radiolog-
ical course. From a therapeutic perspective, these results sug-
gest the potential value of B-cell depletion in early RA, which
is currently under evaluation in controlled trials.
Conclusions
The elevation of markers of B-cell activation in very early RA
demonstrates that B-cell activation is an early pathogenic
event in RA. B-cell activation is not directly driven by a sys-
temic increase of BAFF in early RA. The increase of some
markers of B-cell activation is associated with disease activity,
autoantibody secretion, and early radiological erosion. This
study thus sheds new light on the early pathogenic role of B
lymphocytes in RA and suggests that targeting these cells
might be a useful therapeutic strategy in early RA.
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